Prenatal Antibiotics and Breast Milk / Neonatal IgA

Launched by FONDAZIONE IRCCS CA' GRANDA, OSPEDALE MAGGIORE POLICLINICO · Apr 2, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how prenatal antibiotics, taken by mothers during pregnancy, affect important components in breast milk and the gut bacteria of newborns in their first year of life. Specifically, the researchers want to see how these antibiotics impact the levels of a protective substance called IgA in both breast milk and the baby's stool. They are looking for mothers who have taken antibiotics for at least 7 days after their 32nd week of pregnancy, as well as a control group of mothers who did not take any antibiotics during pregnancy.

To participate, mothers need to be willing to breastfeed their babies for as long as possible during the first year and must provide written consent. However, those who plan to exclusively formula feed or have certain health issues may not be eligible. Participants can expect to provide samples of their breast milk and their baby’s stool over the course of the study, which will help researchers understand the long-term effects of prenatal antibiotics on infant health. This study is currently recruiting participants, and it aims to gather valuable information that could improve care for newborns and breastfeeding mothers.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • expression of written informed consent
• • an antibiotic treatment (any molecule) for at least 7 days consecutively after the 32 weeks of pregnancy (or the absence of exposure to any systemic antibiotic treatment during pregnancy for the control group)
• • the intention to breastfeed their neonates as long as possible during the first year of life
• Exclusion Criteria:
• • absence of written informed consent
• • the intention to formula feed exclusively (or the presence of significant maternal concerns about breastfeeding)
• • a maternal antibiotic treatment shorter than 7 days
• • the presence of pre-existing maternal immune-mediated disorders (including immunodeficiencies and chronic infectious diseases)
• • a delivery at a gestational age \< 34 weeks
• • the administration of antibiotics to neonates after birth, within the first week of life.